Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Healthy
Interventions: rLP2086, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 25 Years
Enrollment: 3,301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Fluoxetine, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 51
States / cities: Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more

Conditions: Prevention From Norovirus Infection
Interventions: Norovirus Bivalent Vaccine, Saline Comparator; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more

Conditions: Cervical Dilation
Interventions: Slight traction, Foley Catheter to no traction; Procedure
Lead sponsor: St. Louis University; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Plantar Fasciitis
Interventions: DAXI 80 U, DAXI 120 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more

Conditions: COVID-19, SARS-CoV 2
Interventions: Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 7 more

Conditions: Anemia, Sickle Cell
Interventions: Glutamine, Placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Asthma
Interventions: Roflumilast; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 39
States / cities: Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 36 more

Conditions: Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
Interventions: DEB-TACE, Sorafenib; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more

Conditions: Osteoarthritis, Knee
Interventions: Vitamin D (cholecalciferol), Placebo; Dietary Supplement
Lead sponsor: Tufts Medical Center; Other
Eligibility: 45 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions: TSW-HP, TSW-T; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions: ALK-001; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Hypokalemia
Interventions: potassium chloride replacement, Experimental - 4% Sodium Bicarbonate; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 21 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Unplanned Hospital Readmissions, Patients at High Risk of Unplanned Readmission
Interventions: Epic 30-day unplanned readmission risk score; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cannabis
Interventions: CBD, THC; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ischemic Stroke
Interventions: 0.05 mL/kg DDFPe, 0.05 mL/kg Placebo, 0.10 mL/kg DDFPe, 0.10 mL/kg Placebo, 0.17 mL/kg DDFPe, 0.17 mL/kg Placebo; Drug
Lead sponsor: NuvOx LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Acute Myocarditis
Interventions: CardiolRx; Drug
Lead sponsor: Cardiol Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Surgery
Interventions: Bright Green Light Therapy, Dim White Light Therapy; Device
Lead sponsor: Rebecca E Kotcher, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Sacituzumab Govitecan, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more

Conditions: Unruptured Cerebral Aneurysm
Interventions: Standard Manual Aneroid Sphygmomanometer; Device
Lead sponsor: Sebastian Koch; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Healthy Participants
Interventions: BMS-986331, Placebo, Matching BMS-986331; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Anaheim, California • Lenexa, Kansas

Conditions: Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions: ceftriaxone, Normal Saline; Drug
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: "Who is Luke Eemia?" Storybook; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 3 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

Norovirus Bivalent-Vaccine Efficacy Study

Balloon Catheter for Cervical Ripening

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Vitamin D to Slow Progression of Knee Osteoarthritis

Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis

Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model

The Pharmacokinetics of a Hemp-Based Topical Product

A Phase Ib/II in Patients With Acute Ischemic Stroke

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

Green Light for Post-Operative Wellness

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Remote Ischemic PreConditioning (RIPC)

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.